Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 2/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | SQOR | Q9Y6N5 | 8/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16113607 | 0.87 | CTSA (0.43) | CTSAPIK3CASQORGRM2FFAR4 | |
| SCHEMBL29501225 | 0.82 | GRM2 (0.42) | CTSASQORGRM2CYP11B1CYP11B2 | |
| SCHEMBL16114254 | 0.82 | GRM2 (0.43) | CTSAPIK3R1PIK3CASQORGRM2 | |
| SCHEMBL16114115 | 0.82 | CTSA (0.42) | CTSASQORGRM2FFAR4KDM4E | |
| SCHEMBL16114492 | 0.82 | GRM2 (0.42) | CTSASQORGRM2CYP11B1CYP11B2 | |
| SCHEMBL16114678 | 0.81 | KMT2A (0.38) | CTSASQORGRM2KMT2A | |
| SCHEMBL20083138 | 0.80 | GRM2 (0.39) | CTSAPIK3R1PIK3CASQORGRM2 | |
| SCHEMBL16113121 | 0.80 | GRM2 (0.52) | CTSASQORGRM2 | |
| SCHEMBL16113549 | 0.80 | LMNA (0.41) | CTSASQORGRM2KDM4EMEN1 | |
| SCHEMBL16114658 | 0.79 | GRM2 (0.51) | CTSASQORGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122172-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC | 2025-04-17 | — | — | US | disclosed |
| US-20230075774-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-03-09 | — | — | US | disclosed |
| US-11279691-B2 | Substituted pyridine and pyrazine compounds as PDE4 inhibitors | DART NEUROSCIENCE LLC (US) | 2022-03-22 | — | — | US | disclosed |
| CN-108299400-B | Substituted pyridine and substituted pyrazine compounds as PDE4 inhibitors | 达特神经科学(开曼)有限公司 | 2021-02-19 | — | — | CN | disclosed |
| EP-3345902-B1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2019-10-30 | — | — | EP | disclosed |
| EP-3345902-B1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2019-10-30 | — | — | EP | disclosed |
| US-20180346448-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2018-12-06 | — | — | US | disclosed |
| EP-3345902-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | Dart NeuroScience (Cayman) Ltd (KY) | 2018-07-11 | — | — | EP | disclosed |
| EP-3345902-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | Dart NeuroScience (Cayman) Ltd (KY) | 2018-07-11 | — | — | EP | disclosed |
| EP-2970212-B1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2018-04-25 | — | — | EP | disclosed |
| EP-2970212-B1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2018-04-25 | — | — | EP | disclosed |
| EP-2970212-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | Dart Neuroscience (Cayman) Ltd (KY) | 2016-01-20 | — | — | EP | disclosed |
| US-20160009691-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE, LLC | 2016-01-14 | — | — | US | disclosed |
| US-20160009691-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE, LLC | 2016-01-14 | — | — | US | disclosed |
| US-20160009691-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE, LLC | 2016-01-14 | — | — | US | disclosed |
| WO-2014158998-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014158998-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346448-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | CTSA 1949/4885PIK3R1 848/4885PIK3CA 222/4885 |
| US-20250122172-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | CTSA 1949/4885PIK3R1 848/4885PIK3CA 222/4885 |
| US-20160009691-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | CTSA 1882/4885PIK3R1 838/4885PIK3CA 215/4885 |
| US-20230075774-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | CTSA 1949/4885PIK3R1 848/4885PIK3CA 222/4885 |
| US-11279691-B2 | Substituted pyridine and pyrazine compounds as PDE4 inhibitors | PDE4A, PDE4B, PDE4D | CTSA 1882/4885PIK3R1 838/4885PIK3CA 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.